Candel Therapeutics, Inc. CADL R2KR3KPHARMA
Company Overview
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.39.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.00% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | +25.47% |
| 6 Months: | +23.54% |
| 3 Months: | -19.38% |
| 1 Month: | -30.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.45 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 41.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CADL Candel Therapeutics, Inc. R2KR3KPHARMA | 8.03 | -5.50 | $614.44M | 0.00% | -41.54% | -81.84% | 0.00% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.00K | 31.00K | 31.00K | 31.00K | 31.00K | 31.00K | 31.00K | 31.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.62M | -2.75M | -4.66M | -5.30M | -8.03M | -8.99M | -8.75M | -8.88M | -9.63M | -9.58M | -8.86M | -7.90M | -8.57M | -8.76M | -8.13M | -11.18M | -13.21M | -16.28M |
| Net Income | -2.88M | -2.55M | -4.48M | -17.08M | -16.16M | -874.00K | -4.15M | -8.69M | -8.79M | -9.61M | -8.44M | -8.22M | -22.24M | -10.65M | 7.38M | -4.80M | -11.27M | -8.86M |
| Diluted EPS | - | - | - | -1.46 | -0.69 | -0.03 | -0.14 | -0.30 | -0.30 | -0.33 | -0.29 | -0.28 | -0.74 | -0.33 | 0.13 | -0.09 | -0.21 | -0.14 |
| R&D Expense | 1.79M | 1.81M | 2.75M | 3.29M | 5.26M | 5.42M | 5.02M | 5.38M | 5.47M | 5.93M | 5.84M | 4.10M | 4.98M | 5.42M | 4.02M | 6.99M | 8.46M | 9.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 125.00K | 125.00K | 125.00K | - | - | - |
| Operating Income | -13.81M | -25.73M | -34.72M | -38.39M | -33.37M | -48.27M |
| Net Income | -17.68M | -36.12M | -18.79M | -37.94M | -55.18M | -38.18M |
| Diluted EPS | - | -1.91 | -0.65 | -1.31 | -1.74 | -0.72 |
| R&D Expense | 8.75M | 15.18M | 20.79M | 24.51M | 19.31M | 30.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 38.28M | 89.20M | 77.69M | 41.20M | 106.87M | 125.19M |
| Total Equity | -8.04M | -23.56M | 64.14M | 47.71M | 12.74M | 66.33M | 51.92M |
| Cash & Equivalents | - | 35.05M | 82.64M | 70.06M | 35.41M | 102.65M | 119.73M |
| Long Term Debt | - | 483.00K | 560.00K | - | 11.63M | 1.73M | - |
| Total Liabilities | - | 12.78M | 25.07M | 29.98M | 28.46M | 40.54M | 73.27M |
| Current Liabilities | - | 4.71M | 5.36M | 5.62M | 14.18M | 37.53M | 9.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.07M | -22.22M | -31.42M | -34.24M | -27.02M | -38.31M |
| Investing Cash Flow | 38.45M | -1.83M | -1.30M | -280.00K | -16.00K | -560.00K |
| Financing Cash Flow | 490.00K | 71.80M | 19.97M | -121.00K | 94.28M | 56.10M |
| Capital Expenditure | -1.48M | -1.83M | -1.30M | -457.00K | -16.00K | -587.00K |
| Free Cash Flow | -10.55M | -24.05M | -32.72M | -34.70M | -27.04M | -38.90M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -11,048.0% | -20,580.8% | -27,777.6% | - | - | - |
| Net Margin % | -14,144.0% | -28,899.2% | -15,035.2% | - | - | - |
| ROE % | 75.0% | -56.3% | -39.4% | -297.7% | -83.2% | -73.5% |
| ROCE % | -41.1% | -30.7% | -48.2% | -142.1% | -48.1% | -41.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.36% | 10.99M | $109.25M |
| 2 | RTW Investments LP | 8.39% | 6.42M | $63.83M |
| 3 | Blackrock Inc. | 6.49% | 4.97M | $49.39M |
| 4 | State Street Corporation | 4.64% | 3.55M | $35.29M |
| 5 | Acorn Capital Advisors, LLC | 4.57% | 3.50M | $34.77M |
| 6 | Portolan Capital Management, LLC | 4.56% | 3.49M | $34.69M |
| 7 | Saturn V Capital Management LP | 4.32% | 3.30M | $32.84M |
| 8 | Vanguard Capital Management LLC | 3.52% | 2.69M | $26.78M |
| 9 | Geode Capital Management, LLC | 2.05% | 1.57M | $15.62M |
| 10 | Millennium Management Llc | 1.43% | 1.09M | $10.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CADL
CADL Apr 2027 5.000 call (CADL270416C00005000) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBLNlQ4UjNjVk1YVFhXcy1oNUZxVHc2OGtjOGczZHZ2Q1ZWeU5pTWk2TUw1aFNBREF5TWowNHU5eDRKTUYzdXhsaTdfYV9sOVdPTEhrdW1wNmc4MjR1X3VuNGJDU0VGQQ?oc=5" target="_blank">CADL Apr 2027 5.000 call (CAD…
A legal executive with 20 years' experience will join Candel as it plans to seek approval for a prostate cancer treatment. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOX01nYlRTQTZFSHYyd3paMXhYa3hoWkpOWTJFLTdRamxNZ1Q5ODVJVHpVRDJtVlp5V29WcUFKZE5fSHBXUEZZUUo0VzhGRWp2U2xLclJad2xsajRLRDRZWkdXdFlnRTVBMkVvcU1hU1hvT2RVRzJzRmNFRm9OcS1TX1dfM1l4WHBTLWNFcm…
H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data - Investing.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPdUQ5LW9oNWFhNXlfTkJySmxTUWV3UFdUVlhxbTNUR2N6VVJ2aVlMYjBoX0J0TTRZMVpHRzhFTE5RbjZoS01JYTc3NGs0QTl4cUFaZVUzTUlrX0hRYkhsc1JSZ2J4QWJXTHJnSnc4SXFWUlMxVXA1WklGcFU3ZUdTaU1JcDNIMUhhaVQ0am…
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxNY3NoVmZZOGhzYlh2U1JaS1hYUjBtcWlMRTgyTUNjOVpidlJVaVg4WV9GUVU2bFdrdzRSS3BOeUFDcTRldTVvdF9FWUFVLUFka0RPanhKVmRxOGhIcDd4M2VaMlhSNExnSnFxc21VS18yT1JEYTRELWlqb2xlRDIxemRueW9wd25Nc2d1MW…
CADL Apr 2027 18.000 call (CADL270416C00018000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1neTRvNjNGM3Vwa0pRb3gwcy01VTlWYVEyQklpdEVNYmJmbjRfdlV5bGF6c3g2Y05xaWozSkJlSldYbWtJalcyMWN0U2FER3NDY2dUVEhLUjExUTltNVVFa0haRmlQZEotOENtT1JB?oc=5" target="_blank">CADL Apr 2027 18.00…
CADL Jan 2027 14.000 put (CADL270115P00014000) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBLclpWQXlFa05CZklvYkVKTW1PcEdBUGpSaHZoM2ZjMkFoNmpJRWJHeGhyNnBCdEZJWWljaWhJMTE0NS1iYjEzSUJ3bjM0anZ6MHV2aWNUUTlaUmxpX1dBdUxtY1BnZw?oc=5" target="_blank">CADL Jan 2027 14.000 put (CAD…
CADL — Frequently Asked Questions
What is the current share price of Candel Therapeutics, Inc. (CADL)?
As of 2026-10-23 16:27 PDT, Candel Therapeutics, Inc. (CADL) trades at $8.03 on NasdaqGM. Its 52-week range is $4.42 to $13.75.
What is the market capitalisation of CADL?
Candel Therapeutics, Inc. (CADL) has a market capitalisation of $614.44M on NasdaqGM.
What is the P/E ratio of CADL?
CADL trades at a trailing price-to-earnings (P/E) ratio of -5.50. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 6.00.
What is the return on equity (ROE) of CADL?
CADL has a return on equity (ROE) of -81.84%. Its return on capital employed (ROCE) is -41.54%.
Is CADL a good stock to buy?
This page provides a data-driven analysis of Candel Therapeutics, Inc. (CADL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.